Ebixa indications extended

The licensed indications for Ebixa (memantine) have been extended to allow its use in the treatment of moderate to severe Alzheimer's dementia. Previously, Ebixa's uses were limited to the treatment of moderately severe to severe Alzheimer's dementia.

The extension to Ebixa's licence follows a meta-analysis of patients with moderate to severe Alzheimer's dementia from six phase III, placebo-controlled, 6-month studies which showed that memantine had a significantly favourable effect in preventing worsening of cognitive, global and functional domains.

Memantine is an NMDA receptor antagonist that modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

View Ebixa drug record

Further Information: Lundbeck Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

Trimbow (beclometasone/formoterol/glycopyrronium) can...